TNGX - CIK 0001819133
Tango Therapeutics, Inc. (TNGX) reported net income of -$101.60M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | -$101.60M | +22.0% |
| FY 2024 | -$130.30M | -28.1% |
| FY 2023 | -$101.70M | +6.0% |
| FY 2022 | -$108.18M | -85.8% |
| FY 2021 | -$58.23M | -12.1% |
| FY 2020 | -$51.97M | - |
Tango Therapeutics, Inc. (TNGX) reported net income of -$101.60M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2020 and fiscal 2025, Tango Therapeutics, Inc.'s net income declined from -$51.97M to -$101.60M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.